A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
复制标题
用于预测人表皮生长因子受体 2 阴性乳腺癌患者病理完全缓解的列线图。
DOI：
10.1186/s12885-016-2652-z
复制
发表时间：
2016-08-05
期刊：
影响因子：
3.8
通讯作者：
Di GH
中科院分区：
文献类型：
--
作者：
Jin X;Jiang YZ;Chen S;Yu KD;Ma D;Sun W;Shao ZM;Di GH
对新辅助化疗的反应已被证明可以预测患者的长期临床获益。本研究旨在构建预测人表皮生长因子受体2阴性乳腺癌患者病理完全缓解的诺模图。我们招募了2003年至2015年接受新辅助化疗的815例患者，并将其分为训练集和验证集。进行单变量逻辑回归筛选预测因子并构建列线图;进行多变量逻辑回归以确定独立预测因子。在训练集中进行单变量logistic回归分析后，肿瘤大小、激素受体状态、新辅助化疗方案和新辅助化疗周期是构建诺模图的最终预测因素。多因素Logistic回归分析显示T4状态、激素受体状态和紫杉醇和卡铂的接受方案是病理完全缓解的独立预测因素。训练集和验证集的受试者工作特征曲线下面积分别为0.779和0.701。我们构建并验证了一个诺模图来预测人表皮生长因子受体2阴性乳腺癌患者的病理完全缓解。我们还确定了肿瘤大小、激素受体状态和紫杉醇和卡铂方案作为病理完全缓解的独立预测因素。本文的在线版本（doi：10.1186/s12885 - 016 - 2652-z）包含补充材料，可供授权用户使用。
The response to neoadjuvant chemotherapy has been proven to predict long-term clinical benefits for patients. Our research is to construct a nomogram to predict pathological complete response of human epidermal growth factor receptor 2 negative breast cancer patients. We enrolled 815 patients who received neoadjuvant chemotherapy from 2003 to 2015 and divided them into a training set and a validation set. Univariate logistic regression was performed to screen for predictors and construct the nomogram; multivariate logistic regression was performed to identify independent predictors. After performing the univariate logistic regression analysis in the training set, tumor size, hormone receptor status, regimens of neoadjuvant chemotherapy and cycles of neoadjuvant chemotherapy were the final predictors for the construction of the nomogram. The multivariate logistic regression analysis demonstrated that T4 status, hormone receptor status and receiving regimen of paclitaxel and carboplatin were independent predictors of pathological complete response. The area under the receiver operating characteristic curve of the training set and the validation set was 0.779 and 0.701, respectively. We constructed and validated a nomogram to predict pathological complete response in human epidermal growth factor receptor 2 negative breast cancer patients. We also identified tumor size, hormone receptor status and paclitaxel and carboplatin regimen as independent predictors of pathological complete response. The online version of this article (doi:10.1186/s12885-016-2652-z) contains supplementary material, which is available to authorized users.